Is Cue Health, Inc. overvalued or undervalued?

As of 10 August 2022, Cue Health, Inc. has moved from an attractive to a risky valuation grade. The company is currently considered overvalued given its significant financial challenges, including a P/E ratio of 0.00 and an EV to EBITDA ratio of 0.19, which indicate a lack of profitability and operational efficiency. Additionally, the company's ROE stands at a staggering -116.50%, reflecting severe losses.
In comparison to its peers, such as Perspective Therapeutics, Inc. with a P/E of -4.32 and Asensus Surgical, Inc. with an EV to EBITDA of -1.53, Cue Health's metrics suggest it is not only underperforming but also facing greater risks. The overall valuation landscape indicates that Cue Health is overvalued, especially considering its recent stock performance, which has shown a drastic decline of 100% over the past year, contrasting sharply with the S&P 500's 10.26% return during the same period.